BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Central Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Central Standard Time
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Central Daylight Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:The PFF hosted a webinar as part of the PFF CTI Webinar Series 
 on Wednesday\, June 4\, 2025. You can now watch the recording to hear from
  people leading trials in pulmonary fibrosis (PF) and interstitial lung di
 sease (ILD) and learn more about studies that are currently recruiting or 
 that have new data to share.🔹 Vicore Pharma AB&nbsp\;A Trial to Evaluate 
 Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fib
 rosis (ASPIRE)James Nolin\, PhD\; Senior Clinical Science Liaison at Vicor
 e Pharma AB🔹 Boehringer IngelheimA Study to Test Whether BI 1839100 Impro
 ves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulm
 onary FibrosisThomas Porter\, MBA\, MPH\; Director\, Clinical Development 
 Lead at Boehringer Ingelheim🔹 Pulmonary Fibrosis Foundation&nbsp\;PFF Com
 munity RegistryJessica Shore\, PhD\, RN\; Senior Vice President\, Clinical
  Affairs and Quality at PFFDISCLAIMER: Participation in the CTI Webinar Se
 ries and references to specific commercial entities (companies) or product
 s do not reflect endorsement by the PFF. The PFF does not endorse or promo
 te any products or services participants discuss in the CTI Webinar Series
 \, and participants cannot suggest otherwise. Please note that any informa
 tion contained in this presentation is for informational and educational p
 urposes only. It is not intended to be a substitute for professional medic
 al advice. Always consult your personal physician or health care provider 
 to determine if a clinical trial is right for you.
DTEND:20250604T180000Z
DTSTAMP:20260514T165201Z
DTSTART:20250604T170000Z
LOCATION:
SEQUENCE:0
SUMMARY:PFF Clinical Trial Innovation (CTI) Webinar Series June 2025
UID:RFCALITEM639143563216162841
X-ALT-DESC;FMTTYPE=text/html:<div>The PFF hosted a webinar as part of the P
 FF CTI Webinar Series on Wednesday\, June 4\, 2025. You can now watch the 
 recording to hear from people leading trials in pulmonary fibrosis (PF) an
 d interstitial lung disease (ILD) and learn more about studies that are cu
 rrently recruiting or that have new data to share.</div><div><br></div><di
 v>🔹 Vicore Pharma AB&nbsp\;</div><div>A Trial to Evaluate Efficacy and Sa
 fety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis (ASPIRE)<
 /div><div>James Nolin\, PhD\; Senior Clinical Science Liaison at Vicore Ph
 arma AB</div><div><br></div><div><br></div><div>🔹 Boehringer Ingelheim</d
 iv><div>A Study to Test Whether BI 1839100 Improves Cough in People With I
 diopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis</div><div>T
 homas Porter\, MBA\, MPH\; Director\, Clinical Development Lead at Boehrin
 ger Ingelheim</div><div><br></div><div><br></div><div>🔹 Pulmonary Fibrosi
 s Foundation&nbsp\;</div><div>PFF Community Registry</div><div>Jessica Sho
 re\, PhD\, RN\; Senior Vice President\, Clinical Affairs and Quality at PF
 F</div><div><br></div><div>DISCLAIMER: Participation in the CTI Webinar Se
 ries and references to specific commercial entities (companies) or product
 s do not reflect endorsement by the PFF. The PFF does not endorse or promo
 te any products or services participants discuss in the CTI Webinar Series
 \, and participants cannot suggest otherwise. Please note that any informa
 tion contained in this presentation is for informational and educational p
 urposes only. It is not intended to be a substitute for professional medic
 al advice. Always consult your personal physician or health care provider 
 to determine if a clinical trial is right for you.</div>
END:VEVENT
END:VCALENDAR